Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Kadmon

Thumbnail
December 09, 2020

Ash 2020 movers – shorts roasting on an open fire

IGM’s snowballing share price belies some other major Ash winners, and will make Christmas unhappy for funds that had shorted the stock.

Thumbnail
December 04, 2020

Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline

Galapagos is betting big in IPF but others, including Fibrogen and Roche, are also taking aim at the lung disease.

Article image
Vantage logo
September 11, 2020

A rare yet early-stage win for Galapagos and Gilead in scleroderma

Article image
Vantage logo
April 23, 2020

The crucial data readouts coming soon for small biotechs

Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.

Article image
Vantage logo
January 09, 2020

Verastem plays the Kras card

For $3m Verastem adds to its pipeline another asset that a bigger company had given up on.

Article image
Vantage logo
January 03, 2020

Beyond Jakafi Incyte fires blanks

Article image
Vantage logo
November 12, 2019

Kadmon sets a high bar in an increasingly competitive space

Article image
Vantage logo
November 04, 2019

SITC 2019 preview – Pieris joins the quest for a better Herceptin

Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.

Article image
Vantage logo
November 01, 2019

Upcoming events – key tests approach for Kadmon and Surface

Kadmon awaits key graft-versus-host disease data, and Surface Oncology's change of tack comes under the spotlight.

Vantage logo
February 13, 2018

Kadmon's lung disease card is not quite an ace

Article image
Vantage logo
April 11, 2017

Calling time on biotech’s shady stock-promotion schemes

The US regulator has come down surprisingly hard on biotech stock promotion schemes.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.